Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 October 2013Website:
http://www.lipocine.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 30 Oct 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
LPCN Latest News
Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity SALT LAKE CITY , Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 data on LPCN 2401 will be presented at the Obesity Society's Annual ObesityWeek® conference to be held November 3 – 6, 2024 in San Antonio, TX.
SALT LAKE CITY , Oct. 23, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference, taking place virtually October 24, 2023.
Lipocine (NASDAQ: LPCN ) stock is rising higher on Thursday after the company released positive results from a Phase 2 clinical trial. That trail covers the use of LPCN 1148 as a treatment for patients suffering from cirrhosis.
What type of business is Lipocine?
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
What sector is Lipocine in?
Lipocine is in the Healthcare sector
What industry is Lipocine in?
Lipocine is in the Biotechnology industry
What country is Lipocine from?
Lipocine is headquartered in United States
When did Lipocine go public?
Lipocine initial public offering (IPO) was on 22 October 2013
What is Lipocine website?
https://www.lipocine.com
Is Lipocine in the S&P 500?
No, Lipocine is not included in the S&P 500 index
Is Lipocine in the NASDAQ 100?
No, Lipocine is not included in the NASDAQ 100 index
Is Lipocine in the Dow Jones?
No, Lipocine is not included in the Dow Jones index
When was Lipocine the previous earnings report?
No data
When does Lipocine earnings report?
The next expected earnings date for Lipocine is 08 November 2024